# Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus

> **NCT01313923** · EARLY_PHASE1 · TERMINATED · sponsor: **University of California, Irvine** · enrollment: 3 (actual)

## Conditions studied

- Pemphigus

## Interventions

- **DRUG:** Sirolimus (formerly known as Rapamycin)

## Key facts

- **NCT ID:** NCT01313923
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2017-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01313923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01313923, "Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01313923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*